Biogen’s Aducanumab: Why Accelerated Approval Might, And Might Not, Be An Option For US FDA

 
• By Sue Sutter
  
conflict in business concept with broken chain
US FDA's advisory committee saw a disconnect between Alzheimer's biomarker data and aducanumab's clinical effects. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers